Aberrant RL2 O-GlcNAc antibody reactivity against serum-IgA1 of patients with colorectal cancer. Verathamjamras C, Sriwitool TE, Netsirisawan P, Chaiyawat P, Chokchaichamnankit D, Prasongsook N, Srisomsap C, Svasti J, Champattanachai V*. Glycoconj J. 2021 Feb;38(1):55-65.

01 Feb 2021
0
0

Aberrant RL2 O-GlcNAc antibody reactivity against serum-IgA1 of patients with colorectal cancer.

Verathamjamras C, Sriwitool TE, Netsirisawan P, Chaiyawat P, Chokchaichamnankit D, Prasongsook N, Srisomsap C, Svasti J, Champattanachai V*.

Glycoconj J. 2021 Feb;38(1):55-65.

Tags

Share this

Related Posts

Andrographis paniculata dissolution investigation and pharmacokinetic studies of four major active diterpeniods after multiple oral dose. Pholphana N, Panomvana D, Rangkadilok N, Suriyo T, Puranajoti P, Ungtrakul T, Pongpun W, Thaeopattha S, Songvut P, Satayavivad J. J Ethnopharmacol 2016; 194: 513-21.
24 Dec 2016
0

Andrographis paniculata dissolution investigation and pharmacokinetic studies of four major active diterpeniods after multiple oral dose. Pholphana N, Panomvana D, Rangkadilok N, Suriyo T, Puranajoti P, Ungtrakul T, Pongpun W, Thaeopattha S, Songvut P, Satayavivad J. J Ethnopharmacol 2016; 194: 513-21.

Andrographis paniculatadissolution investigation and pharmacokinetic studies of four major active diterpeniods after multiple oral dose. Pholphana N, Panomvana D, Rangkadilok N, Suriyo T, Puranajoti P, Ungtrakul T, Pongpun W, Thaeopattha S, Songvut P, Satayavivad J. J Ethnopharmacol 2016; 194: 513-21.
View More

Recent Posts

Efficacy of Andrographis paniculata extract treatment in mild to moderate COVID-19 patients being treated with favipiravir: A double-blind, randomized, placebo-controlled study (APFaVi trial)
New
20 Sep 2023
0
New

Efficacy of Andrographis paniculata extract treatment in mild to moderate COVID-19 patients being treated with favipiravir: A double-blind, randomized, placebo-controlled study (APFaVi trial)

Efficacy of Andrographis paniculata extract treatment in mild to moderate COVID-19 patients being treated with favipiravir: A double-blind, randomized, placebo-controlled study (APFaVi trial) Siripongboonsitti T, Ungtrakul T, Tawinprai K, Auewarakul C, Chartisathian W, Jansala T, Julsawad R, Soonklang K, Mahanonda N, Mahidol C Phytomedicine. 2023;119:155018.
View More